

Special Issue

Disease-Focused Research Using Stem Cells 2.0

Message from the Guest Editor

With advances in stem cell technologies, as well as with the recent availability of genome editing technologies, we can generate more complex and phenotypically accurate cellular models based on stem cells. Reprogramming technology, in particular, which can generate iPS (induced pluripotent stem) cells or directly transdifferentiated cells, enables us to recapitulate patients' symptoms in vitro in cultured cells and/or in vivo in transplanted model animals. This opens new and exciting opportunities for stem cell utilization in early discovery, preclinical and translational research in drug development, and cell therapy.

This Special Issue of *Biomedicines* focuses on recent advances in disease modeling and regenerative medicine using stem cells. The goal is to demonstrate the conceptual and practical advances in order to expand the applications in this exciting field.

Guest Editor

Dr. Yohei Hayashi

iPS Cell Advanced Characterization and Development Team
BioResource Research Center, RIKEN, Tsukuba, Japan
Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-0074, Japan

Deadline for manuscript submissions

closed (31 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/82575

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).